MDWD MediWound Ltd. IFRS
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1593984 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q2*2025-06-30 | 2023Q2*2024-06-30 | 2023Q2*2023-06-30 | 2022Q2*2022-06-30 | 2021Q2*2021-06-30 | 2020Q2*2020-06-30 | 2019Q2*2019-06-30 | 2018Q2*2018-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.71M | $5.06M | $4.77M | $4.67M | $6.06M | $4.03M | $20.75M | $1.03M |
| Cost of revenue | $4.37M | $4.62M | $3.64M | $3.56M | $3.70M | $2.81M | $3.48M | $629,000 |
| Gross profit | $1.34M | $447,000 | $1.14M | $1.11M | $2.36M | $1.22M | $17.27M | $402,000 |
| R&D expense | $3.49M | $1.90M | $2.02M | $2.19M | $2.66M | $1.61M | $172,000 | $1.54M |
| SG&A expense | $2.10M | $1.81M | $1.79M | $1.35M | $1.75M | $1.45M | $1.24M | $842,000 |
| Operating income | -$5.72M | -$4.48M | -$4.01M | -$3.67M | -$2.90M | -$2.71M | $13.94M | -$3.29M |
| Interest expense | $7.99M | $2.40M | $893,000 | $687,000 | $399,000 | $491,000 | $1.31M | $994,000 |
| Pretax income | -$13.28M | -$6.31M | $928,000 | -$4.35M | -$3.18M | -$3.10M | — | — |
| Income tax | $38,000 | -$2,000 | $12,000 | $4,000 | $19,000 | $0 | — | — |
| Net income | -$13.32M | -$6.30M | $916,000 | -$4.35M | -$3.19M | -$3.10M | $12.72M | -$4.17M |
| EBITDA | -$5.32M | -$4.13M | -$3.69M | -$3.35M | -$2.58M | -$2.44M | $14.22M | -$3.12M |
| EPS (basic) | -1.23 | -0.68 | 0.10 | -0.92 | -0.12 | -0.11 | 0.47 | -0.15 |
| EPS (diluted) | -1.23 | -0.68 | 0.10 | -0.92 | -0.12 | -0.11 | 0.47 | -0.15 |
| Weighted avg. shares (diluted) | 10.84M | 9.28M | 9.21M | 4,734 | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.06M | $3.79M | $19.17M | $7.73M | $16.99M | $12.61M | $24.67M | $5.66M |
| Receivables | $5.01M | $2.92M | $3.23M | $3.76M | $2.06M | $2.76M | $570,000 | $779,000 |
| Inventory | $3.84M | $3.21M | $3.11M | $1.99M | $1.40M | $1.93M | $1.53M | $1.87M |
| Current assets | $43.08M | $37.31M | $58.05M | $16.81M | $21.52M | $29.81M | $44.91M | $34.10M |
| PP&E, netmay include right-of-use assets (IFRS) | $15.72M | $12.31M | $4.71M | $2.44M | $2.56M | $2.33M | $2.18M | $2.05M |
| Intangibles | $66,000 | $132,000 | $198,000 | $264,000 | $330,000 | $396,000 | $462,000 | $528,000 |
| Total assets | $67.00M | $57.30M | $64.37M | $21.11M | $26.20M | $34.62M | $49.88M | $36.74M |
| Current liabilities | $29.07M | $22.61M | $17.99M | $10.42M | $9.66M | $9.78M | $10.86M | $5.67M |
| Total liabilities | $46.88M | $39.43M | $29.44M | $23.34M | $24.09M | $24.48M | $31.70M | $35.71M |
| Shareholders' equity | $20.12M | $17.87M | $34.93M | -$2.23M | $2.12M | $10.13M | $18.18M | $1.03M |
| Shares outstanding | 10.88M | 9.29M | 9.22M | 4.73M | 27.25M | 27.21M | 27.18M | 27.18M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.76M | -$3.62M | -$5.25M | -$5.25M | -$985,000 | -$2.81M | $17.27M | -$5.69M |
| Capital expenditure | $1.05M | $3.02M | $1.06M | $138,000 | $26,000 | $100,000 | $194,000 | $197,000 |
| Free cash flow | -$6.80M | -$6.64M | -$6.32M | -$5.39M | -$1.01M | -$2.92M | $17.07M | -$5.88M |
| Investing cash flow | — | — | — | — | — | $7.54M | $232,000 | $1.47M |
| Financing cash flow | $549,000 | -$103,000 | -$405,000 | -$728,000 | -$171,000 | -$153,000 | $91,000 | — |
| Depreciation & amortization | $394,000 | $357,000 | $315,000 | $329,000 | $319,000 | $271,000 | $278,000 | $170,000 |
| Stock-based compensation | $862,000 | $758,000 | $712,000 | $252,000 | $500,000 | $346,000 | $324,000 | $149,000 |
Free plan shows the latest 8 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.